| 5.14 0.24 (4.9%) | 11-05 10:42 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.49 | 1-year : | 7.04 |
| Resists | First : | 5.56 | Second : | 6.03 |
| Pivot price | 5.07 |
|||
| Supports | First : | 4.8 | Second : | 4 |
| MAs | MA(5) : | 5.01  |
MA(20) : | 5.15 |
| MA(100) : | 6.33 |
MA(250) : | 6.93 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 19.8 |
D(3) : | 16.4 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 8.87 | Low : | 4.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CUVL ] has closed below upper band by 33.8%. Bollinger Bands are 58.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.14 - 5.16 | 5.16 - 5.19 |
| Low: | 4.83 - 4.86 | 4.86 - 4.89 |
| Close: | 4.84 - 4.89 | 4.89 - 4.94 |
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.
Wed, 04 Nov 2026
Clinuvel Pharmaceuticals Limited (CUVL) Seasonal returns chart - Yahoo Finance UK
Wed, 04 Nov 2026
Clinuvel Pharmaceuticals Limited (CUVL) Seasonal returns chart - Yahoo Finance Australia
Sun, 01 Nov 2026
Clinuvel Pharmaceuticals Limited (CUVL) stock price, news, quote and history - Yahoo Finance Singapore
Sat, 31 Oct 2026
Clinuvel Pharmaceuticals Limited (CUVL) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 30 Oct 2026
With 210 vitiligo patients enrolled, Clinuvel (CUVL) reports lower operating cash flow. - Stock Titan
Fri, 30 Oct 2026
A second drug goes to EU regulators for Clinuvel (CUVL), with up to three markets possible if approved. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 50 (M) |
| Shares Float | 42 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 12 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | 0.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.79 |
| Profit Margin | 36 % |
| Operating Margin | 47.3 % |
| Return on Assets (ttm) | 8.9 % |
| Return on Equity (ttm) | 13.1 % |
| Qtrly Rev. Growth | -3.8 % |
| Gross Profit (p.s.) | 1.54 |
| Sales Per Share | 1.86 |
| EBITDA (p.s.) | 0.81 |
| Qtrly Earnings Growth | 5.3 % |
| Operating Cash Flow | 37 (M) |
| Levered Free Cash Flow | 25 (M) |
| PE Ratio | 11.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.35 |
| Price to Sales | 2.76 |
| Price to Cash Flow | 7.03 |
| Dividend | 0.03 |
| Forward Dividend | 0 |
| Dividend Yield | 0.7% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|